Search results
Pfizer CEO’s COVID-19 ‘rehearsal’ comment out of context
Politifact· 27 minutes agoA Threads post took a year-old statement by Pfizer CEO Albert Bourla out of context to say the...
The FDA Could, Finally, Approve Novavax's Covid Vaccine — Is Novavax Stock A Buy?
Investor's Business Daily· 15 hours agoSince then, the stock has pulled back. The vaccine is based on protein technology, differentiating...
MSD competes with Pfizer in pneumococcal vaccine market after FDA approval
Pharmaceutical Technology via Yahoo Finance· 4 days agoMSD’s 21-valent pneumococcal vaccine introduces a new rival to Pfizer’s 20-valent product Prevnar 20...
FDA approves Merck vaccine designed to protect adults from bacteria that can cause pneumonia,...
NBC New York· 4 days agoThe Food and Drug Administration approved Merck's vaccine designed to protect adults from a bacteria...
US FDA approves Merck's pneumococcal vaccine for adults
AOL· 4 days agoThe disease can lead to infections in several parts of the body including the lungs, where they can cause pneumonia. Merck's vaccine, branded Capvaxive, helped produce an ...
Merck’s vaccine approval poses threat to one of Pfizer’s top-selling products
Market Watch· 4 days ago“We’ll provide protection that’s broader than anything that’s out there,” Art Hirt, senior vice...
Novavax (NVAX) Seeks FDA Nod for Updated COVID-19 Vaccine
Zacks· 5 days agoNovavax’s filing is based on guidance from the FDA issued last week, which advised COVID-19 vaccine manufacturers Moderna (MRNA Quick QuoteMRNA - Free Report ...
Merck Prepares to Take on Pfizer After Pneumococcal Vaccine Approval
Barrons.com· 4 days agoPfizer currently dominates the market for pneumococcal vaccines, which protect against bacterial...
Pfizer Lingers Near 11-Year Low Despite Promising Cancer Drug Updates — Is It A Sell?
Investor's Business Daily· 2 days agoPfizer is competing against GSK's Arexvy, which hit the market about the same time in 2023. Moderna...
Merck wins FDA OK for vaccine rival to Pfizer’s pneumococcal shot
BioPharma Dive via Yahoo Finance· 4 days agoBut it’s Pfizer’s Prevnar shots that have dominanted the market. The company’s Prevnar...for adults...